Cart
sales@molnova.com
Emavusertib
CAS No. 1801344-14-8
Emavusertib( CA-4948 )
Catalog No. M23815 CAS No. 1801344-14-8
Emavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 40 | In Stock |
|
| 5MG | 63 | In Stock |
|
| 10MG | 80 | In Stock |
|
| 25MG | 160 | In Stock |
|
| 50MG | 295 | In Stock |
|
| 100MG | 507 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEmavusertib
-
NoteResearch use only, not for human use.
-
Brief DescriptionEmavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
-
DescriptionEmavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
-
In Vitro——
-
In VivoAnimal Model:Mice bearing OCI-LY10 tumorsDosage:25, 50, or 150 mg/kg (once daily), 12.5, 25, or 50 mg/kg (twice daily)Administration:Orally, once daily or twice daily, for 14 consecutive days Result:Induced tumor growth inhibition. Emavusertib administered as a twice-daily divided dose was equivalent to the corresponding once-daily dose with regards to antitumor activity, i.e., 12.5 mg/kg BID versus 25 mg/kg QD.
-
SynonymsCA-4948
-
PathwayAngiogenesis
-
TargetFLT
-
RecptorFLT3|IRAK4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1801344-14-8
-
Formula Weight491.5
-
Molecular FormulaC24H25N7O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:27.78 mg/mL (56.52 mM; Need ultrasonic);H2O:< 0.1 mg/mL (insoluble)
-
SMILESCC1=NC=CC(=C1)C2=NC(=CO2)C(=O)NC3=CC4=C(N=C3N5CC[C@H](C5)O)N=C(O4)N6CCOCC6
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Wiese MD, et al. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020 Apr 17:1-8.
molnova catalog
related products
-
FLT3-IN-4
FLT3-IN-4 (FLT3 inhibitor 9u) is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3;?IC50=7 nM) inhibitor ,for treating acute myelogenous leukemia.
-
4SC-203
4SC-203 is a multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs).
-
Gilteritinib hemifum...
Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of relapsed or refractory FLT3 mutant AML.
